HCV Action
The voice of the hepatitis C professional community
I am Medical professionalCommissionerDrug services professional
RT @abbvieuk: Let's work together to find patients living with #HepC so they can get access to treatment quicker. Dedicated funding can sup… — 2 days 16 hours ago
RT @LJWGHepCandSM: Researchers have found that increasing the frequency of hepatitis C screening in gay and bisexual men taking pre-exposur… — 5 days 18 hours ago
RT @HepatitisCTrust: Great to see the UK is on track to eliminate hepatitis C by 2030! Let's push to achieve elimination even sooner... htt… — 5 days 18 hours ago
RT @OneRecBucks: We are so proud that we are able to share our pathway and the work we do for those impacted by #HepC in Bucks. Fantastic p… — 5 days 22 hours ago
*New resource* Our new good practice case study focuses on @OneRecBucks' BBV pathway. Since being implemented in 20… https://t.co/2eo8Mmxkfu — 1 week 1 day ago
Join the HCV Action network for our free monthly email update
Welcome to the resource library, where you can find strategy, research and examples of promising practice in medicine, commissioning and drug services for hepatitis C
Showing 251 to 260 of 307 resources
Display: Most recent first | Alphabetical
Hepatitis C in the UK - 2012 Report
The most recent national estimates in 2012 suggested that around 216,000 individuals were chronically infected with hepatitis C (HCV) in the UK. Both hospital admissions and deaths from HCV-related end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) are continuing to rise. In England, statistical modelling predicts that 15,840 individuals will be living with HCV-related cirrhosis or HCC in England in 2020 if left untreated.
UK Jul 2012 Reports & Research PDF
Testing & Diagnosis, Treatment & Care, Awareness & Prevention
NHS Liver Care E-seminar: Making Every Contact Count
This document provides a summary of the key points made by Professor Martin Lombard, National Clinical Director for Liver Disease, during an NHS presentation he gave. He provides an overview of the high prevalence of liver disease in England and discusses the reasons for this high prevalence and what measures could be taken to lower the number of cases of liver disease. The document also provides a link to listen to the e-seminar.
England 13 Jun 2012 Other MS Word
Hepatitis C Prevalence and Incidence among Scottish Prisoners and Staff Views of its Management: Final Report
This report aims to generate reliable data on prevalence and incidence of hepatitis C to inform the Scottish Prison Service and the NHS to develop effective needs-led interventions for hepatitis C (HCV) infected prisoners, and to enable an informed assessment of the effectiveness of measures to prevent the spread of blood borne viruses, especially hepatitis C, within the prison setting, as outlined in the Hepatitis C (Phase (II)) Action Plan for Scotland (2008).
England, Scotland May 2012 Reports & Research PDF
Prisons, Testing & Diagnosis, Treatment & Care, Awareness & Prevention
Health and Social Care Act 2012
The Health and Social Care Act 2012 aims to safeguard the future of the NHS by modernising it to better tackle the problems of today and avoid crisis tomorrow. It sets out a plan to put clinicians at the centre of commissioning, freeing up providers to innovate, empowering patients and giving a new focus to public health.
England 27 Mar 2012 Other PDF
Testing & Diagnosis, Treatment & Care
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
This paper reports on the results of a 2011 EASL meeting and subsequent dialogue with patient groups and relevant experts in Europe. It summarises the current knowledge of HCV infection and the brain; prevalence, course, and neurobiology of IFN-a associated psychiatric side effects; possible risk factors for IFN-a associated depression and suicide attempts; psychiatric management of HCV infected patients before and during antiviral treatment; prevention of IFN- a associated psychiatric side effects; and psychiatric aspects of the new antivirals.
UK, Rest of World 2012 Reports & Research PDF
Deaths from liver disease: Implications for end of life care in England - March 2012
This report presents key facts about deaths from liver disease in England. It highlights differences in place and cause of death by age, sex and deprivation. It is aimed at commissioners and providers of end of life care, clinicians caring for patients with liver disease, and others concerned with providing quality end of life care for this patient group, including patients themselves and their carers. The report gives the first summary of high level statistics on deaths from liver disease on which future discussions can be built.
England Mar 2012 Reports & Research PDF
Guidance on testing for hepatitis B and C (with reference to HIV) Developed by Yorkshire and the Humber Hepatitis B and C Steering Group
Individuals with chronic hepatitis (B and C) can be treated, which reduces the likelihood of chronic illness and premature death. Recognition of infection and treatment may also reduce the spread of infection. In 2010 across Yorkshire and the Humber there were 427 cases of hepatitis B (of which 39 were acute) and 980 newly identified hepatitis C infections reported through NHS/HPA laboratory testing, however HPA estimates calculate that there are over 20,000 people actually infected with hepatitis C in the region.
Yorkshire and the Humber Mar 2012 Tools & Templates, Strategy & Planning PDF
Yorkshire and the Humber Quality Standards Framework for Hepatitis B and C: 2012
In order to address the prevention and burden of hepatitis C (and B) effectively it is important that the four key elements of the pathway are in place as defined by the Department of Health. Whilst there have been many developments since 2004, this Quality Standards Framework still focuses on the four key elements of the hepatitis B and C pathway but provides more detail on how, in Yorkshire and the Humber, stakeholders can work effectively to deliver a quality pathway to patients regarding hepatitis B and C.
Yorkshire and the Humber 2012 Other, Reports & Research PDF
The Silent Pandemic: Tackling Hepatitis C with Policy Innovation
Hepatitis C may be the serious disease that most combines widespread prevalence with widespread ignorance. According to the World Health Organisation (WHO), this urgent public health problem kills 350,000 people per year, and 150 million have the chronic form of the hepatitis C virus (HCV). The incidence of new infections is simply not known at the global level. Yet, HCV is entirely preventable and largely curable.
Improving outcomes and supporting transparency. Part 1: A public health outcomes framework for England, 2013-2016
The responsibility to improve and protect our health lies with us all – government, local communities and with ourselves as individuals.
England Jan 2012 Reports & Research, Strategy & Planning PDF
Treatment & Care, Awareness & Prevention
Drug services professional
South Asian Communities
Sort by Published dateTitle
Royal College of Nursing (RCN)
Hepatitis C Trust
British Society of Gastroenterology (BSG)
World Hepatitis Alliance (WHA)
Funding and support for HCV Action is provided by Gilead Sciences Ltd, Abbvie and Merck Sharp & Dohme.